TY - JOUR

T1 - Strategies to manage hepatitis C virus (HCV) disease burden

AU - Wedemeyer, H

AU - Duberg, A S

AU - Buti, M

AU - Rosenberg, W M

AU - Frankova, S

AU - Esmat, G

AU - Örmeci, N

AU - Van Vlierberghe, H

AU - Gschwantler, M

AU - Akarca, U

AU - Aleman, S

AU - Balık, I

AU - Berg, T

AU - Bihl, F

AU - Bilodeau, M

AU - Blasco, A J

AU - Brandão Mello, C E

AU - Bruggmann, P

AU - Calinas, F

AU - Calleja, J L

AU - Cheinquer, H

AU - Christensen, P B

AU - Clausen, M

AU - Coelho, H S M

AU - Cornberg, M

AU - Cramp, M E

AU - Dore, G J

AU - Doss, W

AU - El-Sayed, M H

AU - Ergör, G

AU - Estes, C

AU - Falconer, K

AU - Félix, J

AU - Ferraz, M L G

AU - Ferreira, P R

AU - García-Samaniego, J

AU - Gerstoft, J

AU - Giria, J A

AU - Gonçales, F L

AU - Guimarães Pessôa, M

AU - Hézode, C

AU - Hindman, S J

AU - Hofer, H

AU - Husa, P

AU - Idilman, R

AU - Kåberg, M

AU - Kaita, K D E

AU - Kautz, A

AU - Kaymakoglu, S

AU - Krajden, M

AU - Krarup, H

AU - Laleman, W

AU - Lavanchy, D

AU - Lázaro, P

AU - Marinho, R T

AU - Marotta, P

AU - Mauss, S

AU - Mendes Correa, M C

AU - Moreno, C

AU - Müllhaupt, B

AU - Myers, R P

AU - Nemecek, V

AU - Øvrehus, A L H

AU - Parkes, J

AU - Peltekian, K M

AU - Ramji, A

AU - Razavi, H

AU - Reis, N

AU - Roberts, S K

AU - Roudot-Thoraval, F

AU - Ryder, S D

AU - Sarmento-Castro, R

AU - Sarrazin, C

AU - Semela, D

AU - Sherman, M

AU - Shiha, G E

AU - Sperl, J

AU - Stärkel, P

AU - Stauber, R E

AU - Thompson, A J

AU - Urbanek, P

AU - Van Damme, P

AU - van Thiel, I

AU - Vandijck, D

AU - Vogel, W

AU - Waked, I

AU - Weis, N

AU - Wiegand, J

AU - Yosry, A

AU - Zekry, A

AU - Negro, F

AU - Sievert, W

AU - Gower, E

N1 - © 2014 John Wiley & Sons Ltd.

PY - 2014

Y1 - 2014

N2 - The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.

AB - The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Antiviral Agents

KW - Diagnostic Tests, Routine

KW - Disease Eradication

KW - Drug Therapy, Combination

KW - Female

KW - Global Health

KW - Hepatitis C, Chronic

KW - Humans

KW - Incidence

KW - Male

KW - Middle Aged

KW - Models, Statistical

KW - Prevalence

KW - Young Adult

U2 - 10.1111/jvh.12249

DO - 10.1111/jvh.12249

M3 - Journal article

C2 - 24713006

VL - 21

SP - 60

EP - 89

JO - Journal of Viral Hepatitis

JF - Journal of Viral Hepatitis

SN - 1352-0504

IS - s1

ER -